Advanced Enzyme Technologies (ADVENZYMES) 주식 개요
Advanced Enzyme Technologies Limited는 자회사와 함께 인도, 유럽, 미국, 아시아 및 국제적으로 효소 및 프로바이오틱스의 연구, 개발, 제조 및 마케팅에 종사하고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 ADVENZYMES에 대한 위험이 감지되지 않았습니다.
ADVENZYMES Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Advanced Enzyme Technologies Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | ₹386.20 |
| 52주 최고가 | ₹419.00 |
| 52주 최저가 | ₹251.95 |
| 베타 | 0.69 |
| 1개월 변동 | 29.75% |
| 3개월 변동 | 23.41% |
| 1년 변동 | 33.77% |
| 3년 변동 | 39.95% |
| 5년 변동 | -18.46% |
| IPO 이후 변동 | 40.42% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.내러티브 업데이트 • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.내러티브 업데이트 • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Recent updates
내러티브 업데이트 • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.내러티브 업데이트 • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.내러티브 업데이트 • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.내러티브 업데이트 • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.내러티브 업데이트 • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.내러티브 업데이트 • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).분석 기사 • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...새로운 내러티브 • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.분석 기사 • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...분석 기사 • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...분석 기사 • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...분석 기사 • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...분석 기사 • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...분석 기사 • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...분석 기사 • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...분석 기사 • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...분석 기사 • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...분석 기사 • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...분석 기사 • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...분석 기사 • Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...분석 기사 • Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...주주 수익률
| ADVENZYMES | IN Chemicals | IN 시장 | |
|---|---|---|---|
| 7D | 5.7% | 0.7% | 0.5% |
| 1Y | 33.8% | -2.6% | -0.7% |
수익률 대 산업: ADVENZYMES은 지난 1년 동안 -2.6%의 수익을 기록한 Indian Chemicals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ADVENZYMES은 지난 1년 동안 -0.7%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 6.4% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
안정적인 주가: ADVENZYMES는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ADVENZYMES의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1957 | 338 | n/a | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited는 자회사와 함께 인도, 유럽, 미국, 아시아 및 국제적으로 효소 및 프로바이오틱스의 연구, 개발, 제조 및 마케팅에 종사하고 있습니다. 이 회사는 인간 건강 관리 및 동물 영양, 과일 및 채소 가공, 제빵, 양조 및 양조, 전분 및 곡물 가공, 단백질 변형, 효모 가공, 유제품 및 치즈 가공, 오일 및 지방 가공, 특수 응용 분야, 바이오 연료 및 바이오 촉매를 위한 효소 및 프로바이오틱스 기반 영양 보충제를 제공합니다. 섬유, 가죽, 펄프 및 제지 가공을 위한 비식품 가공 효소는 물론 세제 및 세척 보조제를 제공합니다.
Advanced Enzyme Technologies Limited 기초 지표 요약
| ADVENZYMES 기초 통계 | |
|---|---|
| 시가총액 | ₹43.23b |
| 순이익 (TTM) | ₹1.69b |
| 매출 (TTM) | ₹7.81b |
25.6x
주가수익비율(P/E)5.5x
주가매출비율(P/S)ADVENZYMES는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ADVENZYMES 손익계산서 (TTM) | |
|---|---|
| 매출 | ₹7.81b |
| 매출원가 | ₹1.93b |
| 총이익 | ₹5.88b |
| 기타 비용 | ₹4.19b |
| 순이익 | ₹1.69b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 15.07 |
| 총이익률 | 75.28% |
| 순이익률 | 21.61% |
| 부채/자본 비율 | 1.2% |
ADVENZYMES의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.3%
현재 배당 수익률38%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 19:26 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Advanced Enzyme Technologies Limited는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |